Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera–Suggestion to Be Added to Be One of the Minor Criterion

Jen C. Wang *, Guanfang Shi, Stacey Baptiste, Maryna Yarotska, Hemant Sindhu, Ching Wong, Madhumati Kalavar, Vladimir Gottlieb, Andrei Bandarchuk, Hui Chen

Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, United States of America

* jcwang0005@Gmail.com

Abstract

Endogenous erythroid colony (EEC) formation is one of the minor criteria for diagnosing polycythemia vera (PV) according to 2008 WHO diagnostic criteria. But EEC requires bone marrow aspiration and sophisticated laboratory procedures; therefore, practically it is rarely used to diagnose PV. Insulin-like growth factor 1 receptor (IGF-1R) was found to be constitutively phosphorylated and was responsible for the EEC formation in PV; therefore, we measured IGF-1R levels in the peripheral blood of 26 PV patients and compared them with those of 33 patients with secondary polycythemia and 29 normal controls. Among the PV patients, 16 were treated with only phlebotomy, 9 received hydroxyurea, and 1 was treated with ruxolitinib. We found that PV patients treated with only phlebotomy had significantly higher IGF-1R levels than did those PV patients treated with hydroxyurea or ruxolitinib. None of the secondary PV patients or normal controls had elevated IGR-1R levels, while 14 of 16 (87%) PV patients had significantly elevated IGF-1R levels. The new 2016 WHO has eliminated EEC as a minor criterion for diagnosing PV, but there are still some cases that cannot be definitively diagnosed by the current criteria. Therefore, we suggest that quantifying the IGF-1R level in peripheral blood by flow cytometry to replace EEC as the minor criterion for diagnosing PV.

Introduction

The WHO criteria 2008 for diagnosing PV use the JAK2 mutation as one of the major criteria for diagnosing PV [1], which can help establish a diagnosis in most cases of PV [2,3]. The minor criteria included endogenous erythroid colony (EEC) formation in vitro, bone marrow (BM) trilineage proliferation, and serum erythropoietin (EPO) levels. EEC was first reported in the culture of BM from PV patients without added EPO [4], which was later found in the culture of peripheral blood (PB) as well [5,6]. This test has been the specific test for diagnosing PV...
since 1980 prior to the JAK2 era [5–8]. However, this test has been found to be impractical and is seldom used to diagnose PV. The reasons have been methodological, since the greatest specificity and sensitivity have been observed when BM, as opposed to PB, was used [9]; moreover, the in vitro clonal assay is neither standardized nor widely available [10]. Therefore, EEC has been deleted in the proposed criteria [11] and adopted by the new 2016 WHO criteria [12] for diagnosing PV.

Increased tyrosine phosphorylation of the insulin-like growth factor 1 receptor (IGF-1R) in circulating mononuclear cells (MNC) of PV patients was reported by Mirza et al. [13]. It was also found that IGF-1, but not EPO, is responsible for EEC formation in PV [14,15]. Hence, we revisited the IGF-1R pathway in PV and found increased IGF-1R expression by flow cytometry in nearly 90% of patients with PV but not in secondary polycythemia. Because the newly revised criteria still cannot cover all the cases of PV, we suggest replacing EEC formation with PB IGF-1R level measured by flow cytometry as one of the minor criteria for diagnosing PV.

Materials and Methods

Patients

All myeloproliferative neoplasm (MPN) patients were diagnosed according to 2008 WHO criteria. PB was obtained from patients with written informed consent; the protocol was approved by the IRB of Brookdale University Hospital. Twenty-six patients with PV (16 received only phlebotomy (untreated); 9 were treated with hydroxyurea and 1 with ruxolitinib), 33 with secondary polycythemia (23 were secondary to heavy smoking, 5 were secondary to testosterone injection, and 5 with high EPO levels and BM morphology negative for trilineage hyperproliferation), and 29 normal volunteer controls were studied. The studies were done from January 2013 until December 2015. The clinical features of the 16 untreated PV patients are listed and their clinical features are presented in Table 1. Most patients had JAK2 V617F mutation. One patient was diagnosed based on increased red blood cell mass, BM trilineage hypercellularity, relating to employment, consultancy, patents, products in developments, or marketing products. This does not alter our adherence to the PLOS ONE policy on sharing data and/or materials. The other authors declare no competing financial interests.

Table 1. Characteristics of Phlebotomized Only PV patients.

| Patient | Age/gender | JAK-2 | WBC/Platelet (x10^9/ml) | Spleen (CM) | HX of Thrombosis | IGF-1R |
|---------|------------|-------|-------------------------|-------------|------------------|--------|
| 1       | 73/M       | 28.7%* | 12.3/756                | 11          | N                | 38.08  |
| 2       | 78/M       | positive | 10.0/430               | 11          | N                | 323.8  |
| 3       | 70/F       | positive | 9.0/425                 | 11          | N                | 35.2   |
| 4       | 72/M       | positive | 11.2/450                | 11          | N                | 461.7  |
| 5       | 71/F       | positive | 9.0/433                 | 11          | N                | 324.9  |
| 6       | 72/M       | 67%    | 18.2/288                | 18          | N                | 983    |
| 7       | 51/F       | positive | 20.5/732                | 11          | N                | 350    |
| 8       | 61/M       | positive | 19.5/691                | 11          | N                | 414    |
| 9       | 74/M       | positive | 13.6/873                | 11          | Y                | 505.9  |
| 10      | 69/F       | 86%    | 12.1/489                | 16          | N                | 459.4  |
| 11      | 65/F       | Negative** | 5.5/170               | 11          | N                | 202    |
| 12      | 69/F       | 91%    | 29.5/896                | 16          | N                | 353.5  |
| 13      | 70/F       | 37%    | 4.8/354                 | 11          | N                | 1082   |
| 14      | 69/F       | 8%     | 18.7/677                | 11          | N                | 374.03 |
| 15      | 89/F       | positive | 26/226                 | 11          | N                | 182    |
| 16      | 81/M       | 20%    | 13.0/153                | 11          | N                | 369.5  |

* denotes percentage of allele-burden of JAK2V617F
** Diagnosis was made by the bone marrow and increased of RBC mass.

doi:10.1371/journal.pone.0165299.t001
and low EPO level. S1 Table, we showed the clinical data on the patient with PV who were treated with hydroxyurea or ruxolitinib.

Flow Cytometry
MNC were isolated from PB by gradient centrifugation with Ficoll-Paque. MNC were then washed with buffer and incubated with fluorophore-conjugated primary antibody or isotype controls for 30 min at room temperature and analyzed by FACS Calibur System (BD Biosciences, San Jose, CA). PE-conjugated antibody against human IGF-1R was purchased from R&D Systems (Minneapolis, MN). APC-conjugated antibody against human CD33 and FITC-conjugated antibodies against human CD14 and CD34 were purchased from BD Pharmingen. Median fluorescence intensity was calculated using FlowJo software.

Statistical Analyses
Data were summarized by median and interquartile range. The Kruskal-Wallis test was used to test the difference of distribution among patient groups. Pairwise comparisons between each group post Kruskal-Wallis test were performed with Dunn’s test. To define a cutoff value of IGF-1R to predict patient’s diagnosis as PV or secondary polycythemia, logistic regression was used to model the data, and the cutoff was chosen based on the value that provided the best classification.

Results
IGF-1R was measured by median fluorescence intensity and expressed as median and interquartile range. As shown in Fig 1, untreated PV patients had significantly higher IGF-1R (361.5, 227.8–461.1) than did secondary polycythemia patients (58.13, 15.46–90.43), normal controls (49.20, 14.63–113.5), and treated PV patients (52.29, 23.89–149.3) ($P < 0.05$). Logistic regression showed that IGF-1R was a statistically significant ($P = 0.003$) predictor of a patient’s group (PV or secondary polycythemia). A cutoff value of 163 was determined from the logistic regression to predict a patient’s group; an IGF-1R $\geq 163$ suggested that a patient belonged to the PV group. In our cohort, 14 of 16 PV patients were diagnosed based on IGF-1R $\geq 163$ and; while 2 of 16 patients with JAK2V617F-positive PV had lower values, the sensitivity of this test was 87.5% and specificity was 100%. Significantly elevated IGF-1R values were found in PV patients, while no secondary polycythemia patients had high IGF-1R. Therefore, we demonstrated that diagnosing PV can be achieved by assaying IGF-1R levels with flow cytometry of PB without doing BM biopsy. The procedure is much easier and quicker than EEC tests, which need sophisticated laboratory procedures and take longer to perform.

To elucidate which cell population contributed to the elevation of IGF-1R MFI, four PV patients with elevated IGF-1R were studied. As shown in Fig 2, with IGF-1R values of MNC population set at 100%, IGF-1R of CD33$^-\,$CD34$^-$ cells were 58.59±14.23%; CD33$^+$CD34$^-$ cells were 82.07±14.03; CD33$^-$CD34$^+$ cells were 163.6±21.5%; and CD33$^+$CD34$^+$ cells were 195.3±7.5%. Therefore, increased IGF-1R expressions in PV were mostly from the CD33$^+$CD34$^+$ cell population, not from the CD33$^-\,$CD34$^-$ cell population.

To elucidate further the use of IGF-1R by flow cytometry to diagnose other MPN diseases, 19 patients with essential thrombocythemia (ET), 28 myelofibrosis (MF) patients including 5 post-ET-MF, 5 post-PV-MF, and 18 primary myelofibrosis (PMF) patients were compared with PV patients and controls. The patients who were treated with hydroxyurea and ruxolitinib were excluded. The results are presented in Fig 3: ET patients (183.0, 86.8–327.0) ($n = 19$) and MF patients (135.1, 73.01–247.6) ($n = 28$) had significantly elevated IGF-1R levels compared with controls (47.75, 34.50–68.79) ($n = 30$), and PV patients appeared to have more
Fig 1. IGF-1R expression is significantly increased in patients with polycythemia vera. A) Representative flow cytometry analysis of IGF-1R (measured by MFI) in patients with untreated PV (received only phlebotomy), secondary polycythemia, normal controls, and treated PV (treated with hydroxyurea or...
significantly elevated levels than did ET or MF patients. To correlate JAK2 positive vs. negative in relation to IGF-1R levels in all MPN patients; although JAK2+ patients had more elevated values (160.6, 47.15–325.4) (n = 46) than did JAK2− patients (115.2, 66.61–280.6) (n = 25), no statistically significant correlation was found (results not shown).

Discussion

Barbui and Tefferi [11] proposed revising WHO diagnostic criteria for PV and adopted by WHO in 2016 [12] as follows: 1) increased RCM, and/or Hb > 16.5 g in men, > 16 g in women or Hct > 49% in men, > 48% in women; 2) BM morphology consistent with WHO criteria; and 3) presence of JAK2 mutation; minor criterion: serum EPO levels. This proposal eliminates EEC and emphasizes BM findings and RCM.

BM biopsy was emphasized as the major criterion in the new WHO 2016 criteria for PV. it is characterized as showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with ruxolitinib. B) Untreated PV patients have significantly increased IGF-1R (measured by MFI), results were expressed as median, interquartile range in PV (361.5, 227.8–461.1), secondary polycythemia (58.13,15.46–90.43), controls (49.20,14.63–113.5), and treated PV (52.29,23.89–149.3) (P<0.05).

doi:10.1371/journal.pone.0165299.g001

Fig 2. IGF-1R expression is mostly from CD34+ and CD33+ cell population. Four PV patients with elevated IGF-1R were studied. Flow cytometry analysis was done to investigate which cell populations produce IGF-1R. Setting IGF-1R (MFI) of mononuclear cell population values as 100%. CD33 CD34− cells were found to be 58±14%; CD33+CD34+, 135.7±41%; CD33−CD34+, 163.6±21.5%; CD33+CD34+, 195.3±7.5%. Therefore, IGF-1R expression was mostly from CD34+ and CD33+ cell populations.

doi:10.1371/journal.pone.0165299.g002
pleomorphic, mature megakaryocytes (differences in size). This characteristic bone marrow finding for diagnosing PV has been published in many reports [16–22]. But in some cases, BM examination still needs expert hematopathologists to read the results correctly, and the results may not be reproducible due to interobserver variation. A critical attitude concerning the value of BM examinations for discriminating PV from other subtypes of MPDs, as well as from reactive erythrocytosis or secondary polycythemia, has been expressed [23–26]. In the Polycythemia Vera Study Group (PVSG), an analysis of BM morphology in 281 PV patients followed for more than 9 years [23] showed that 13% of the patients did not have increased marrow cellularity or megakaryocyte hyperplasia at diagnosis. Thiele et al. also reported that of 334 patients with erythrocytosis, 4% patients could not be clearly differentiated into primary vs. secondary PV [24]. Thus, for 4–13% of patients, BM biopsy will not suitably differentiate PV from secondary erythrocytosis. For EPO levels, subnormal values were recorded in around 60% of PV patients and, in turn, normal values were found in 20% of unquestioned cases with BM morphology typical of PV [27]. Therefore, we feel that, in some small percentage of cases, PV still cannot be definitively diagnosed by BM or serum EPO levels in the cases in which JAK2, CALR, or MPL gene mutations were negative.

In our small cohort of patients, we could clearly diagnose PV in 87% of cases, and none of the secondary erythrocytosis patients had elevated IGF-1R by flow cytometry; one patient with
negative JAK2V617F mutation also had trilineage proliferation of bone marrow, increased RCM, and low serum EPO who was diagnosed as PV also had elevated IGF-1R values as other PV patients. We believe that, in a small percentage of cases, assaying IGF-1R by flow cytometry can be added to the definitive diagnosis of PV. Thus, we suggest that measuring IGF-1R in the PB samples is a simple, easy, not an invasive test, (like BM biopsy) and to be added to the minor criteria for diagnosing PV.

We also found other Philadelphia chromosome -negative MPN (Ph-MPN) patients (hydroxyurea- and ruxolitinib-naïve ET and MF patients) had significantly increased IGF-1R relative to controls (Fig 3). Our ongoing studies will further analyze whether this can also help to differentiate the diagnosis between primary ET and secondary ET and MF cases.

Cross-talk between IGF-1R and the JAK2 V617F mutation has been demonstrated [28]. Therefore, IGF-1R levels were compared between JAK2 V617F mutation positive and negative MPN patients; no statistical significance was found. Two ET patients with a CALR-positive mutation and one with an MPL mutation were also found to have highly elevated IGF-1R expression, and two other CALR-positive ET patients were found to have normal IGF-1R values as controls. Hence, it appears that elevated IGF-1R is not correlated to JAK2V617F mutation status.

A low percentage allele burden of JAK2⁺ (<37%) was found in some patients in our series (Table 1). Different methods in measuring allele burden could accounted for the difference [29]; real-time PCR methods are less sensitive than direct sequencing, assessing alle expression (AS-PCR), or pyrosequencing. Some of the samples were performed by a commercial lab in 2010 where real-time PCR methods were used which could have explained the relative lower values than other series.

Supporting Information
S1 Table. Characteristics of hydroxyurea /ruxolitinib treated PV patients.
(DOCX)

Acknowledgments
The authors thank Dr. Ruqin Chen and Dr. Shuguang Chen for assistance with the statistical analyses.

Author Contributions
Conceptualization: JCW GS.
Data curation: JCW MK CW.
Formal analysis: JCW GS.
Funding acquisition: JCW VG.
Investigation: JCW MK VG AB HC.
Methodology: GS SB MY JCW.
Project administration: JCW VG.
Resources: JCW VG MK CW.
Software: AB HC HS.
Supervision: JCW VG.
Validation: JCW SB MY.
Visualization: GS SB MY VG AB HC.
Writing – original draft: JCW HS.
Writing – review & editing: JCW HS.

References
1. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood. 2007; 110(4):1092–1097 doi: 10.1182/blood-2007-04-083501 PMID: 17488875
2. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007; 21(9):1960–1963 doi: 10.1038/sj.leu.2404810 PMID: 17597810
3. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia. 2008; 22(7):1299–1307 doi: 10.1038/leu.2008.113 PMID: 18496562
4. Prchal JF, Axelrad AA. Bone marrow responses in polycythemia vera [letter]. N Engl J Med. 1974; 290:1382
5. Lutton JD, Levere RD. Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera. Acta haemat. 1979; 62:94–99 PMID: 119408
6. Lacombe C, Casadevall N, Varet B. Polycythemia vera: in vitro studies of circulating erythroid progenitors. Br J Haematol. 1980; 44:189–199
7. Zanjani ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro: dependence on erythropoietin. J Clin Invest. 1977; 59:841–848 doi: 10.1172/JCI108706 PMID: 853125
8. Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood. 1978; 52:1196–1210 PMID: 719172
9. Weinberg RS, Worsley A, Gilbert HS, Cuttner J, Berk PD, Alter BP. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Leuk Res. 1989; 13:331–338 PMID: 2716348
10. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002; 100(13):4272–4290 doi: 10.1182/blood-2001-12-0349 PMID: 12393615
11. Barbui T, Thie J, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocytemia and primary myelofibrosis. Blood Cancer Journal 2015; 5, e337 doi: 10.1038/bcj.2015.64 PMID: 26832847
12. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405. doi: 10.1182/blood-2016-03-643544 PMID: 27069254
13. Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor 1 receptor p subunit in circulating mononuclear cells of patients with polycythemia vera. Blood. 1995; 86:877–882 PMID: 7542500
14. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium. Blood. 1994; 83:99–112 PMID: 8274756
15. Lacombe C, Casadevall N, Varet B. Polycythemia vera: in vitro studies of circulating erythroid progenitors. Br J Haematol. 1980; 44:189–199 PMID: 7378297
16. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013; 122:1881–1886. doi: 10.1182/blood-2013-06-508416 PMID: 23900239
17. Barbui T, Thie J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014; 89:52–54 doi: 10.1002/ajh.23585 PMID: 23996471
18. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocytemia. Acta Haematol 2005; 113:213–219 doi: 10.1159/000084673 PMID: 15903426

PLOS ONE | DOI:10.1371/journal.pone.0165299 November 3, 2016 8 / 9
19. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocytemia. *Am J Clin Pathol* 2008; 130:336–342 doi: 10.1309/6BQ5K8LHVYAYUAF4 PMID: 18701405

20. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). *Histol Histopathol* 2005; 20:317–328 PMID: 15578448

21. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. *Am J Hematol* 2010; 85:62–66 doi: 10.1002/ajh.21543 PMID: 19844986

22. Gianelli U, Bossi A, Cortinovis I, Sabattini E, Tripodo C, Boveri E et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. *Mod Pathol* 2014; 27:814–822 doi: 10.1038/modpathol.2013.196 PMID: 24201120

23. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. *Semin Hematol* 1986; 23:144–155 PMID: 3704666

24. Thiele J, Kvasnicka HM, Diehl V. Bone marrow features of diagnostic impact in erythrocytosis. *Ann Hematol* 2005; 84:362–367 doi: 10.1007/s00277-005-1030-8 PMID: 15803315

25. Alvarez-Larrán A, Ancochea A, García M. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. *Br J Haematol* 2014; 166(6):911–919. doi: 10.1111/bjh.12990 Epub 2014 Jun 24 PMID: 24957246

26. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocytemia: interobserver reliability and utility for identifying disease subtypes. *Blood* 2008; 111(1):60–70 doi: 10.1182/blood-2007-05-091850 PMID: 1785079

27. Mossuz P, Giridon F, Donnand M, Latger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. *Haematologica* 2004; 89;1194–1198 PMID: 15477203

28. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. *J Biol Chem* 2005; 280(51):41883–41899 doi: 10.1074/jbc.C500358200 PMID: 16239216

29. Kim HR, Choi HJ, Kim YK, Kim HJ, Shin JH, Suh SP, et al. Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms. *PLoS One* 2013; 8(1):e52518. doi: 10.1371/journal.pone.0052518 Epub 2013 Jan 22 PMID: 23349688